Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-03-04

Clinical Trial Update: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program. [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial update reports completion and posted results for the combination of peginterferon alfa-2a and ribavirin in patients with chronic hep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Copegus (ribavirin)
  • Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2016-03-04